Stockscreener 앱 받기
72.09
0.48%
-0.35
시간 외 거래:
72.08
-0.01
-0.01%
Astrazeneca PLC 주식(AZN)의 최신 뉴스
Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN) | AZN Stock News - GuruFocus
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma - BioPharma Dive
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma - Yahoo Finance
AstraZeneca reports success in phase III asthma trials By Investing.com - Investing.com India
AstraZeneca reports success in phase III asthma trials - Investing.com
AstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trials - Reuters
AstraZeneca (AZN) Achieves Major Milestones in Asthma Treatment Trials - GuruFocus
AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials - insights.citeline.com
AstraZeneca's (AZN) Breztri Aerosphere Achieves Key Milestones i - GuruFocus
AstraZeneca posts phase 3 win for asthma drug (AZN:NASDAQ) - Seeking Alpha
AstraZeneca’s asthma therapy shows promise in trials By Investing.com - Investing.com UK
AstraZeneca (AZN) Triple Therapy Shows Promise in Asthma Trials - GuruFocus
AstraZeneca (AZN) Triple Therapy Shows Promise in Asthma Trials | AZN Stock News - GuruFocus
AstraZeneca’s share price is down 20% from September, so is it time for me to buy? - MSN
AstraZeneca's Asthma Drug Improves Lung Function in Late-stage Studies - marketscreener.com
AstraZeneca Plc Breztri succeeds in Phase III asthma trials - DirectorsTalk Interviews
AstraZeneca's Breztri meets main goals of late-stage asthma trials - marketscreener.com
AstraZeneca and AI startup join forces in the fight against lung cancer - Mugglehead Magazine
AstraZeneca Director Buys ADSs Worth Over $100,000 - Investing.com
AstraZeneca reports total voting rights - Investing.com
AstraZeneca quietly exits neuroscience - BioPharma Dive
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Benzinga
AstraZeneca (AZN) Reports Strong Q1 Earnings and Reiterates Guid - GuruFocus
Up 7.5% in a week! Is the GSK share price about to do an AstraZeneca? - Yahoo
AstraZeneca Faces Intensified Probe in China as Tax Evasion Amount Grows - Caixin Global
Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC - Clinical Trials Arena
AstraZeneca (AZN) Contemplates U.S. Production Expansion Amid Ta - GuruFocus
AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Call Transcript - Insider Monkey
AstraZeneca has plenty coming down the pipeline to appease the bears - Proactive Investors
AstraZeneca’s Truqap fails in another Phase III trial - Yahoo Finance
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... - Yahoo Finance
AstraZeneca - Britannica
AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong R - GuruFocus
AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... By GuruFocus - Investing.com Canada
PRESS DIGEST-British BusinessApril 30 - marketscreener.com
BofA Securities Keeps AstraZeneca at Buy as Q1 EPS Tops Consensus - marketscreener.com
AstraZeneca’s Calquence gets CHMP nod for CLL in the EU By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
EU panel backs AstraZeneca’s Calquence for CLL treatment - Investing.com
AstraZeneca’s Calquence gets CHMP nod for CLL in the EU - Investing.com
AstraZeneca halts phase III trial of prostate cancer drug By Investing.com - Investing.com India
AstraZeneca halts phase III trial of prostate cancer drug - Investing.com
AstraZeneca CEO calls for increased European investment in pharma - Pharmaceutical Technology
AstraZeneca Loses IP Shield For Diabetes Drug - Law360
Astrazeneca Does not Expect Material Long-Term Impact From US Tariffs, CEO Says - marketscreener.com
AstraZeneca (AZN) Q1 2025 Earnings Highlight 10% Revenue Growth - GuruFocus
AstraZeneca shares claw their way back into green after revenue miss - Proactive Investors
AstraZeneca CEO: Trump tariffs 'not material long term' - Yahoo Finance
AstraZeneca says potential US tariffs manageable, faces another China fine - marketscreener.com
AstraZeneca (AZN) Stock: Strong Q125 Growth Bolsters Path to $80B Revenue Goal - CoinCentral
FTSE 100 makes late surge after AstraZeneca, BP and AB Foods setbacks - Proactive Investors
Astrazeneca's Fixed-Duration Calquence-Based Regimen Receives CHMP Recommendation for Leukaemia - marketscreener.com
AstraZeneca ends trial for prostate cancer drug (AZN:NASDAQ) - Seeking Alpha
AstraZeneca's 'number 1 priority' is the US, CEO says - Yahoo Finance
AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty - Benzinga
FTSE 100 Live: AstraZeneca and BP weigh, while Amazon in White House firing line - Proactive Investors
AstraZeneca shows its strength despite sales miss - Proactive Investors
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
AstraZeneca gets EU backing for lymphocytic leukemia treatment - Seeking Alpha
AstraZeneca moves some production to US amid tariff threat - Yahoo
Here’s why the AstraZeneca share price dipped 3.7% in the FTSE 100 today - Yahoo
FTSE 100 Live: Stocks crawl higher after AstraZeneca, BP and AB Foods hit brakes - Proactive Investors
AstraZeneca (AZN) Confirms 2025 Sales Forecast Amid Potential U. - GuruFocus
AstraZeneca (AZN) Reports Q1 Revenue Below Expectations, Highlig - GuruFocus
AstraZeneca (AZN) Halts CAPItello-280 Trial for Prostate Cancer Treatment | AZN Stock News - GuruFocus
자본화:
|
볼륨(24시간):